INTELLIA THERAPEUTICS, INC. (NTLA) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 59.51M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $59.51M | (m) | (m) |
| 2026-03-31 | (m) | $66.09M | (m) | (m) |
| 2025-12-31 | (m) | $67.67M | (m) | (m) |
| 2025-09-30 | (m) | $57.53M | (m) | (m) |
| 2025-06-30 | (m) | $52.86M | (m) | (m) |
| 2025-03-31 | (m) | $45.57M | (m) | (m) |
| 2024-12-31 | (m) | $57.88M | (m) | (m) |
| 2024-09-30 | (m) | $43.09M | (m) | (m) |
| 2024-06-30 | (m) | $45.97M | (m) | (m) |
| 2024-03-31 | (m) | $52.60M | (m) | (m) |
| 2023-12-31 | (m) | $36.27M | (m) | (m) |
| 2023-09-30 | (m) | $51.77M | (m) | (m) |
| 2023-06-30 | (m) | $53.04M | (m) | (m) |
| 2023-03-31 | (m) | $53.48M | (m) | (m) |
| 2022-12-31 | (m) | $52.12M | (m) | (m) |
| 2022-09-30 | (m) | $51.40M | (m) | (m) |
| 2022-06-30 | (m) | $45.34M | (m) | (m) |
| 2022-03-31 | (m) | $37.86M | (m) | (m) |
| 2021-12-31 | (m) | $33.05M | $0.00 | (m) |
| 2021-09-30 | (m) | $26.79M | (m) | (m) |
| 2021-06-30 | (m) | $41.81M | (m) | (m) |
| 2021-03-31 | (m) | $51.52M | (m) | (m) |
| 2020-12-31 | (m) | $57.99M | $0.00 | (m) |
| 2020-09-30 | (m) | $62.34M | (m) | (m) |
| 2020-06-30 | (m) | $50.73M | (m) | (m) |
| 2020-03-31 | (m) | $45.59M | (m) | (m) |
| 2019-12-31 | (m) | $43.10M | $0.00 | (m) |
| 2019-09-30 | (m) | $40.05M | $0.00 | (m) |
| 2019-06-30 | (m) | $36.84M | $0.00 | (m) |
| 2019-03-31 | (m) | $33.40M | (m) | (m) |
| 2018-12-31 | (m) | $30.43M | $0.00 | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $27.37M | (m) | (m) |
| 2017-12-31 | (m) | $26.12M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $16.48M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |